CCL4 Protein, Human, Recombinant (His) is expressed in yeast with His tag. The predicted molecular weight is 9.2 kDa and the accession number is P13236.
| 説明 |
CCL4 Protein, Human, Recombinant (His) is expressed in yeast with His tag. The predicted molecular weight is 9.2 kDa and the accession number is P13236. |
| Species |
Human
|
| Expression Host |
P. pastoris (Yeast)
|
| Tag |
C-His
|
| Accession Number |
P13236
|
| 別名 |
SCYA2, G-26, MIP-1-β, LAG-1, MIP1B, AT744.1, SCYA4, MIP-1-beta, chemokine (C-C motif) ligand 4, ACT2, MIP1B1, LAG1, HC21
|
| Construction |
Human CCL4 (NP_002975.1) (Ala24-Gln92) was expressed with a polyhistidine tag at the C-terminus.
|
| Protein Purity |
> 90 % as determined by SDS-PAGE
|
| 分子量 |
9.2 kDa (predicted)
|
| Endotoxin |
Please contact us for more information.
|
| Formulation |
Lyophilized from a solution filtered through a 0.22 μm filter, containing 0.1% TFA. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
|
| Reconstitution |
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
|
| Stability & Storage |
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
|
| Shipping |
In general, Lyophilized powders are shipping with blue ice.
|
| Research Background |
CCL4 (C-C chemokine ligand 4), is a macrophage inflammatory protein with a chief effect in inflammation and immune-regulation, and was documented in cancer progression by promoting instability in the tumor environment. The inflammatory chemokine (C-C motif) ligand 4 (CCL4) plays an important role in the pathogenesis and progression of cancer. In particular, higher serum CCL4 levels in patients with oral squamous cell carcinoma (OSCC) are associated with a more advanced stage of disease. CCL4 may be a new molecular therapeutic target for inhibition of lymphangiogenesis and metastasis in OSCC. CCL3 and CCL4 loci may be marker SNPs for risk of HCV treatment outcome. CCL4 can enhance the recruitment of preosteoclasts to bone in the early stage, and the reduction of CCR5 promotes osteoclastogenesis when RANKL is prevalent.
|
Calculator
Reconstitution Calculator
Recombinant Proteins Dilute Calculator
Specific Activity Calculator
bottom
